Health
Virus drug benefit only marginal: study – Tenterfield Star
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly short…
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.
The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.
The 600-patient analysis, published on Friday by the Journal of the American Medi…
-
Noosa News21 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Business22 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
Business13 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
Noosa News24 hours ago‘They’re not taking the concerns of women seriously’